Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
RNXT 
RenovoRx Inc (RNXT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: RNXT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5.62
1 Year Target Price $5.62
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -39.69% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 46.91M USD | Price to earnings Ratio - | 1Y Target Price 5.62 |
Price to earnings Ratio - | 1Y Target Price 5.62 | ||
Volume (30-day avg) 4 | Beta 1.23 | 52 Weeks Range 0.75 - 1.69 | Updated Date 09/14/2025 |
52 Weeks Range 0.75 - 1.69 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.38 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -634.6% |
Management Effectiveness
Return on Assets (TTM) -54.82% | Return on Equity (TTM) -107.11% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 34852731 | Price to Sales(TTM) 70.86 |
Enterprise Value 34852731 | Price to Sales(TTM) 70.86 | ||
Enterprise Value to Revenue 52.65 | Enterprise Value to EBITDA -4.72 | Shares Outstanding 36645900 | Shares Floating 30083339 |
Shares Outstanding 36645900 | Shares Floating 30083339 | ||
Percent Insiders 4.44 | Percent Institutions 24 |
Upturn AI SWOT
RenovoRx Inc
Company Overview
History and Background
RenovoRx, Inc. is a biopharmaceutical company founded in 2009 and based in Los Altos, California. It focuses on developing and commercializing targeted therapies for solid tumors.
Core Business Areas
- Targeted Cancer Therapies: RenovoRx develops innovative therapies that deliver chemotherapy directly to the tumor, reducing systemic side effects.
Leadership and Structure
Shaun R. Bagai is the CEO. The company has a typical structure with a board of directors and executive management team overseeing research, development, and clinical operations.
Top Products and Market Share
Key Offerings
- RenovoCath: A proprietary catheter designed to deliver chemotherapy directly to tumors via intra-arterial delivery. Revenue is currently minimal as the company is still in the clinical trial and pre-commercialization phase. Competitors include companies offering drug-delivery systems for cancer, although RenovoRx's focus on regional chemotherapy delivery provides differentiation.
- RenovoGem: Gemcitabine delivered via RenovoCath. Revenue is currently minimal as the company is still in the clinical trial and pre-commercialization phase. Competitors include other chemotherapy delivery methods and systemic chemotherapy regimens.
Market Dynamics
Industry Overview
The oncology market is large and growing, driven by aging populations and increasing cancer incidence. There is a growing trend towards personalized medicine and targeted therapies.
Positioning
RenovoRx aims to position itself as a leader in targeted intra-arterial chemotherapy delivery for solid tumors. Its competitive advantage lies in its proprietary delivery system and focus on reducing systemic toxicity.
Total Addressable Market (TAM)
The TAM for targeted cancer therapies is substantial, projected to be in the tens of billions of dollars. RenovoRx is targeting a niche within this market, focusing on solid tumors treatable with regional chemotherapy, which may represent a TAM in the hundreds of millions to billions of dollars, dependent on the approved treatment.
Upturn SWOT Analysis
Strengths
- Proprietary drug delivery system (RenovoCath)
- Potential for reduced systemic toxicity
- Targeted therapy approach
- Experienced management team
Weaknesses
- Limited financial resources
- Clinical trial risk
- Dependence on single product platform
- Lack of established commercial infrastructure
Opportunities
- Positive clinical trial results
- Partnerships with pharmaceutical companies
- Expansion to new tumor types
- FDA approval and commercialization
Threats
- Competition from established cancer therapies
- Regulatory hurdles
- Failure of clinical trials
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- MRK
- BMY
- GILD
Competitive Landscape
RenovoRx's advantages lie in its proprietary delivery system and targeted approach. Its disadvantages include its small size, limited resources, and dependence on clinical trial success.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is minimal due to the pre-commercialization stage.
Future Projections: Future growth is dependent on the success of clinical trials and subsequent commercialization of RenovoCath and RenovoGem. Analyst estimates vary widely.
Recent Initiatives: Focus on completing clinical trials for RenovoGem for pancreatic cancer, and expanding trials into other solid tumors
Summary
RenovoRx is a high-risk, high-reward biopharmaceutical company. Its success hinges on the outcome of its clinical trials and subsequent commercialization. While its targeted therapy approach is promising, it faces significant competition and regulatory hurdles. The company is still early in the trials process.
Peer Comparison
Sources and Disclaimers
Data Sources:
- RenovoRx Inc. SEC Filings
- Company Website
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Financial data is based on publicly available information and may not be completely accurate. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About RenovoRx Inc
Exchange NASDAQ | Headquaters Mountain View, CA, United States | ||
IPO Launch date 2021-08-26 | CEO, Secretary & Director Mr. Shaun R. Bagai | ||
Sector Healthcare | Industry Biotechnology | Full time employees 10 | Website https://renovorx.com |
Full time employees 10 | Website https://renovorx.com | ||
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.